Patient characteristics
| . | Aspirin users (n = 132) . | Aspirin nonusers (n = 464) . | P value . |
|---|---|---|---|
| Demographics | |||
| Age mean (SD) | 64.8 (8.1) | 61 (10.6) | <.001 |
| Sex, female | 50 (37.9%) | 295 (63.6%) | <.001 |
| Race | |||
| White or Caucasian | 113 (85.6%) | 411 (88.6%) | .10 |
| Black or African American | 5 (3.8%) | 26 (5.6%) | |
| Asian | 7 (5.3%) | 19 (4.1%) | |
| American Indian and Alaska Native | 1 (0.8%) | 0 (0.0%) | |
| Other | 2 (1.5%) | 5 (1.1%) | |
| Patient refused | 2 (1.5%) | 2 (0.4%) | |
| Unknown | 2 (1.5%) | 1 (0.2%) | |
| Comorbidities | |||
| Diabetes mellitus | 41 (31.1%) | 44 (9.5%) | <.001 |
| Hypertension | 83 (62.9%) | 178 (38.4%) | <.001 |
| Chronic kidney disease | 8 (6.1%) | 21 (4.5%) | .49 |
| CHF | 3 (2.3%) | 10 (2.2%) | 1.00 |
| OSA | 36 (27.3%) | 110 (23.7%) | .42 |
| Anemia | 3 (2.3%) | 0 (0%) | .01 |
| Cirrhosis/liver disease | 1 (0.8%) | 0 (0%) | .22 |
| BMI mean (SD) | 31 (5.8) | 29.5 (6.3) | .04 |
| Tobacco use | |||
| Current | 5 (3.8%) | 28 (6%) | .34 |
| Former | 46 (34.8%) | 183 (39.4%) | |
| Never | 81 (61.4%) | 253 (54.5%) | |
| Heavy alcohol use | 3 (2.3%) | 0 (0%) | .01 |
| Medication characteristics | |||
| Aspirin on medication list | 108 (81.8%) | 61 (13.1%) | <.001 |
| Clopidogrel | 0 (0%) | 0 (0%) | 1.00 |
| Celecoxib | 2 (1.5%) | 14 (3.0%) | .54 |
| Rivaroxaban, apixaban, low molecular weight heparin | 2 (1.5%) | 12 (2.6%) | .75 |
| NSAID EHR | 29 (22%) | 232 (50%) | <.001 |
| NSAID self-report | 19 (14.4%) | — | — |
| Aspirin use past 2 wk | — | — | |
| 11-14 d | 116 (87.9%) | — | — |
| 7-10 d | 13 (9.8%) | — | — |
| 4-6 d | 3 (2.3%) | — | — |
| Years of aspirin use | — | — | |
| 0-2 y | 15 (11.4%) | — | — |
| 3-5 y | 21 (15.9%) | — | — |
| 6-10 y | 40 (30.3%) | — | — |
| 11-20 y | 34 (25.8%) | — | — |
| >20 y | 22 (16.7%) | — | — |
| Dose ≤81 mg | 117 (89.3%) (n = 131) | — | — |
| Initiating provider | — | — | |
| PCP | 83 (62.9%) | — | — |
| Self | 21 (15.9%) | — | — |
| Cardiology | 11 (8.3%) | — | — |
| Specialist (other than cardiology) | 10 (7.6%) | — | — |
| Recommendation of family or friend | 4 (3.0%) | — | — |
| Other | 3 (2.3%) | — | — |
| Admission related to bleeding | 19 (14.4%) | 54 (11.6%) | .45 |
| Major bleeding (self-report) | 1 (0.8%) | 0 (0%) | .22 |
| Falls | 6 (4.6%) | — | — |
| Heartburn | 21 (15.9%) | — | — |
| Peptic ulcer | 2 (1.5%) | — | — |
| Rating of overall health (Median and IQR) | 8 [7-8] | — | — |
| . | Aspirin users (n = 132) . | Aspirin nonusers (n = 464) . | P value . |
|---|---|---|---|
| Demographics | |||
| Age mean (SD) | 64.8 (8.1) | 61 (10.6) | <.001 |
| Sex, female | 50 (37.9%) | 295 (63.6%) | <.001 |
| Race | |||
| White or Caucasian | 113 (85.6%) | 411 (88.6%) | .10 |
| Black or African American | 5 (3.8%) | 26 (5.6%) | |
| Asian | 7 (5.3%) | 19 (4.1%) | |
| American Indian and Alaska Native | 1 (0.8%) | 0 (0.0%) | |
| Other | 2 (1.5%) | 5 (1.1%) | |
| Patient refused | 2 (1.5%) | 2 (0.4%) | |
| Unknown | 2 (1.5%) | 1 (0.2%) | |
| Comorbidities | |||
| Diabetes mellitus | 41 (31.1%) | 44 (9.5%) | <.001 |
| Hypertension | 83 (62.9%) | 178 (38.4%) | <.001 |
| Chronic kidney disease | 8 (6.1%) | 21 (4.5%) | .49 |
| CHF | 3 (2.3%) | 10 (2.2%) | 1.00 |
| OSA | 36 (27.3%) | 110 (23.7%) | .42 |
| Anemia | 3 (2.3%) | 0 (0%) | .01 |
| Cirrhosis/liver disease | 1 (0.8%) | 0 (0%) | .22 |
| BMI mean (SD) | 31 (5.8) | 29.5 (6.3) | .04 |
| Tobacco use | |||
| Current | 5 (3.8%) | 28 (6%) | .34 |
| Former | 46 (34.8%) | 183 (39.4%) | |
| Never | 81 (61.4%) | 253 (54.5%) | |
| Heavy alcohol use | 3 (2.3%) | 0 (0%) | .01 |
| Medication characteristics | |||
| Aspirin on medication list | 108 (81.8%) | 61 (13.1%) | <.001 |
| Clopidogrel | 0 (0%) | 0 (0%) | 1.00 |
| Celecoxib | 2 (1.5%) | 14 (3.0%) | .54 |
| Rivaroxaban, apixaban, low molecular weight heparin | 2 (1.5%) | 12 (2.6%) | .75 |
| NSAID EHR | 29 (22%) | 232 (50%) | <.001 |
| NSAID self-report | 19 (14.4%) | — | — |
| Aspirin use past 2 wk | — | — | |
| 11-14 d | 116 (87.9%) | — | — |
| 7-10 d | 13 (9.8%) | — | — |
| 4-6 d | 3 (2.3%) | — | — |
| Years of aspirin use | — | — | |
| 0-2 y | 15 (11.4%) | — | — |
| 3-5 y | 21 (15.9%) | — | — |
| 6-10 y | 40 (30.3%) | — | — |
| 11-20 y | 34 (25.8%) | — | — |
| >20 y | 22 (16.7%) | — | — |
| Dose ≤81 mg | 117 (89.3%) (n = 131) | — | — |
| Initiating provider | — | — | |
| PCP | 83 (62.9%) | — | — |
| Self | 21 (15.9%) | — | — |
| Cardiology | 11 (8.3%) | — | — |
| Specialist (other than cardiology) | 10 (7.6%) | — | — |
| Recommendation of family or friend | 4 (3.0%) | — | — |
| Other | 3 (2.3%) | — | — |
| Admission related to bleeding | 19 (14.4%) | 54 (11.6%) | .45 |
| Major bleeding (self-report) | 1 (0.8%) | 0 (0%) | .22 |
| Falls | 6 (4.6%) | — | — |
| Heartburn | 21 (15.9%) | — | — |
| Peptic ulcer | 2 (1.5%) | — | — |
| Rating of overall health (Median and IQR) | 8 [7-8] | — | — |
All data from the patient survey apart from admission related to bleeding, comorbidities other than cirrhosis and anemia, demographics, and concomitant medications (aspirin and NSAIDs) were reviewed by the medical records and the survey. Data not provided by the patient surveys were identified from the EHR.
CHF, congestive heart failure; IQR, interquartile range; OSA, obstructive sleep apnea; PCP, primary care provider; SD, standard deviation.